The Venture Codex Logo

The Venture Codex

Japanese International Cooperation Agency

Nibancho Center Building, 5-25 Niban-cho, Tokyo, Chiyoda-ku, 102-8012, Japan

Overview

The Japan International Cooperation Agency (JICA) is advancing its activities around the pillars of a field-oriented approach, human security, and enhanced effectiveness, efficiency and speed.

Total investments
1
Lead investments
0
Investments · 12mo
0
Active investors
3

Sector focus

  • Government
  • Service Industry
  • Social
Visit website

Investment portfolio

  • dr.consulta

    Participated · Series D · Aug 2023

    Dr.Consulta operates a digital-first healthcare ecosystem that includes an electronic medical record, clinician-created protocols based on international standards, data intelligence and use of artificial intelligence to integrate the patient journey from initial consultation to high-complexity care. The company says its model resolves roughly 80% of patient needs within its clinics, referring patients to credentialed hospitals only when necessary. Over the past two years Dr.Consulta averaged about 2 million visits and reported 14.5% growth in the first half of 2023 versus the second half of 2022. The startup positions itself to further strengthen its presence in the telemedicine market following its latest fundraise. Its platform and clinical protocols are a core part of its value proposition to improve access to higher-quality, technology-enabled healthcare in Brazil. dr.consulta is a healthtech that provides consultations, exams and a coordinated primary-to-secondary care ecosystem through physical clinics and digital tools. The company operates a proprietary electronic medical record, clinical protocols and in-house data intelligence to coordinate patient journeys. It reports approximately 4.5 million registered users (about 30% of São Paulo’s population) and achieved R$310 million in revenue in 2021 with positive EBITDA margin. dr.consulta says its semi-verticalized model resolves about 80% of patient needs in-house and focuses on clinical outcomes and patient satisfaction (medical satisfaction 90% and NPS 84). Future plans include consolidating and expanding its health-and-technology ecosystem, scaling an owned health-plan offering via a partnership with cuidar.me, and continued investment in technology and clinical innovation.

Team

  • Shinichi Kitaoka

    President

  • Ryutaro Murotani

    Deputy Head, Office for Global Issues and Development Partnership

    LinkedIn
  • Ikuo Takizawa

    Deputy Director General of Human Development Department

    LinkedIn